Ohr Pharmaceutical appoints Jason Slakter to its Board of Directors

– USA, NY – Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that Jason Slakter, MD, Chief Medical Officer, has been appointed to the Company’s Board of Directors.

“Since joining our management team in June of last year, Dr. Slakter has been instrumental in continuing to move our ocular-focused development programs forward,” said Dr. Irach Taraporewala, Chief Executive Officer of Ohr Pharmaceutical. “He is an internationally recognized retinal and macular disease specialist, and has provided significant insight for our clinical development strategies.”

“I am extremely pleased to join the Ohr Board at such a critical time in the Company’s history,” said Dr. Slakter. “We achieved clinical momentum in 2014, and intend to continue that progress in 2015. We will have a number of important milestones throughout the first half of the calendar year, beginning with reporting of final clinical data from the IMPACT study in wet-AMD. We also expect to commence our planned Phase III clinical trials of OHR-102 for the treatment of wet AMD as well as releasing data from our two investigator sponsored clinical trials evaluating OHR-102 in proliferative diabetic retinopathy and retinal vein occlusion.”

Dr. Slakter is a Clinical Professor of Ophthalmology at New York University School of Medicine and has a clinical practice at the Vitreous-Retina-Macula Consultants in New York, N.Y. He is involved extensively in the design and application of new diagnostic and therapeutic modalities for the treatment of a variety of ophthalmic diseases. He has served as a principal investigator in many of the clinical trials for new therapies for the management of exudative age-related macular degeneration, diabetic retinopathy, retinal vascular disease and central serous chorioretinopathy. Dr. Slakter is the founder and director of the Digital Angiography Reading Center (DARC) in New York, which is one of the largest centers for image evaluation for clinical trials of posterior segment disease with over 850 certified clinical sites in over 44 countries worldwide. He is a member of numerous medical organizations including The Macula Society, The Retina Society, and The American Society of Retina Specialists, and he was the founding Editor-in-Chief of Retinal Physician journal. He has been the recipient of many awards including The Macula Society’s Richard and Hinda Rosenthal Award for outstanding contribution to the treatment of ocular disease by an individual under the age of 45, as well as the Helen Keller Manhattan League Award in 2003. Dr. Slakter has published more than 100 papers and book chapters.

Dr. Slakter was one of the co-founders of SKS Ocular, which was acquired by Ohr in June of 2014. He joined Ohr as Chief Medical Officer upon closing of the transaction.

About Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical, Inc. (OHRP) is an ophthalmology research and development company. The company’s lead product, Squalamine, is currently being studied as an eye drop formulation in several company sponsored and investigator sponsored Phase II clinical trials for various back-of-the-eye diseases, including the wet form of age-related macular degeneration, retinal vein occlusion, diabetic macular edema, and proliferative diabetic retinopathy. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery. The company also has a research agreement with Alcon on a sustained release program.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>